Lisata Therapeutics

Emily Jarvie, a journalist with experience in political, business, legal, and scientific reporting, joined Proactive in 2022. Proactive provides independent financial news globally, focusing on medium and small-cap markets, and uses technology to enhance content production while maintaining human authorship.

Lisata Therapeutics announced the first patient dosing in the second-line cholangiocarcinoma cohort of the BOLSTER trial, following successful enrollment in the first-line cohort. The study evaluates certepetide in combination with standard-of-care for CCA, aiming to improve outcomes for patients.

The FDA granted orphan drug designation to certepetide for treating cholangiocarcinoma, an investigational agent enhancing anticancer drug penetration into tumors. Certepetide is being studied in the phase 2a BOLSTER trial (NCT05712356), with 80 patients randomized into four arms, focusing on adverse event incidence.

FDA grants orphan drug designation to certepetide for cholangiocarcinoma. Certepetide is being evaluated in phase 2 BOLSTER trial with SOC therapies. It enhances drug delivery and tumor microenvironment modulation. BOLSTER trial includes first- and second-line treatments with certepetide. Certepetide also has ODD for malignant glioma, osteosarcoma, and pancreatic cancer.